Home›Oncology› TORS yields oncologic outcomes comparable to radiotherapy in early-stage oropharyngeal cancer
TORS yields oncologic outcomes comparable to radiotherapy in early-stage oropharyngeal cancerRobotic surgery shows promise as an alternative to radiation therapy
Frontiers in MedicinePublished August 19, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider TORS as a de-intensification option for early-stage OPSCC, but weigh limited functional outcome evidence.
This systematic review synthesized evidence from 51 clinical trials, with 23 publications and 3 abstracts retrieved, to compare transoral robotic surgery (TORS) with radiotherapy for oropharyngeal squamous cell carcinoma (OPSCC). The primary outcome was oncologic outcomes, with secondary outcomes including toxicity profiles and functional outcomes.
The authors found that oncologic outcomes with TORS were comparable to radiotherapy in early-stage OPSCC, with no difference in this outcome. Toxicity profiles were distinct but generally acceptable. The review also supported the feasibility of treatment de-escalation, suggesting that reduced-dose or omission of adjuvant radiotherapy may be considered in carefully selected HPV-positive patients without compromising survival outcomes.
However, the authors noted a key limitation: high-quality evidence remains limited regarding functional outcomes from advancements in perioperative management and robotic technology. This means that while oncologic outcomes appear similar, the impact on functional results is less certain.
In practice, TORS may serve as a de-intensification strategy in carefully selected patients with OPSCC. Biomarkers such as cfHPVDNA may help with risk stratification, but this is mentioned as a potential aid rather than a proven tool.
Overall, this review supports the role of TORS as an alternative to radiotherapy in early-stage disease, but clinicians should interpret the evidence with caution given the limitations in functional outcome data.
How this fits prior evidence
This systematic review confirms and extends prior coverage on HPV-positive OPSCC. It aligns with the finding that HPV is strongly associated with oropharyngeal SCC, and supports the concept of treatment de-escalation in HPV-positive patients, as suggested by the multidimensional adaptive treatment model. It also complements prior evidence on radiotherapy improvements by showing that TORS offers comparable oncologic outcomes, providing an alternative de-intensification strategy. However, it does not directly address molecular drivers of resistance or compare IMPT versus IMRT, leaving those areas for further investigation.
Living with a throat cancer diagnosis often means facing intense treatments like radiation. New evidence suggests that transoral robotic surgery (TORS) can be an effective alternative for certain patients. This method allows doctors to treat the cancer through the mouth using robotic tools, which may change how patients experience their recovery.
Researchers looked at 51 clinical trials involving people with oropharyngeal squamous cell carcinoma. They found that for those in early stages of the disease, robotic surgery produced outcomes comparable to traditional radiotherapy. This means the survival rates were similar between the two methods, making surgery a viable option for specific cases.
For some patients who test positive for HPV, doctors may even be able to reduce or skip certain radiation steps without hurting their chances of survival. While the data shows that side effects from robotic surgery are distinct but generally acceptable, more high-quality evidence is still needed to fully understand how it affects long-term physical function.
What this means for you:
Robotic surgery offers comparable survival rates to radiation for early-stage throat cancer and may allow less intense treatment.
Common questions
Is robotic surgery as effective as radiation for throat cancer?
For patients with early-stage oropharyngeal squamous cell carcinoma, the study found that transoral robotic surgery provides outcomes comparable to radiotherapy. This means both methods were equally effective at managing the cancer's progression in these specific cases.
Can some patients avoid radiation after having robotic surgery?
Yes, for carefully selected patients who are HPV-positive, the data supports reducing or even skipping certain radiation treatments. This can be done without compromising survival outcomes, making it a potential way to lessen the intensity of treatment.
What are the side effects of robotic surgery?
The study found that while the toxicity profiles for robotic surgery are distinct from radiation, they are generally acceptable. However, more high-quality evidence is still needed to fully understand how advancements in technology affect long-term functional outcomes.
BackgroundHuman papillomavirus (HPV) has substantially altered the epidemiology and prognosis of oropharyngeal squamous cell carcinomas (OPSCC), with an increasing incidence in younger patients and markedly improved survival outcomes. This shift presents an increasing clinical challenge: how to safely reduce treatment intensity, while maintaining cure and survival rates and minimizing therapy-related toxicity. Transoral robotic surgery (TORS) has emerged as a pivotal strategy in this context, with multiple clinical trials demonstrating promising outcomes. This review aims to summarize registered clinical trials evaluating TORS in OPSCC, identify existing gaps in the literature, and highlight directions for future research.MethodsA systematic search of ClinicalTrials.gov was conducted between May 2024 and January 2026 using the search terms “TORS” and “transoral robotic surgery.” The search included completed and analyzed studies, as well as completed but unanalyzed, ongoing or planned studies. Relevant publications were retrieved from databases including ClinicalTrials.gov, PubMed and The Cochrane Library. As this study was based on publicly available literature and trial registries, ethical committee approval was not required.ResultsA total of 51 clinical trials were identified. We retrieved a total of 23 publications and 3 abstracts. Across these studies, TORS demonstrated oncologic outcomes comparable to radiotherapy in early-stage OPSCC, with distinct but generally acceptable toxicity profiles. Several trials supported the feasibility of treatment de-escalation, including reduced-dose or omission of adjuvant radiotherapy in carefully selected HPV-positive patients, without compromising survival outcomes. Emerging evidence from biomarker-driven studies suggests that circulating cell-free HPV DNA (cfHPVDNA) may enable improved risk stratification and guide personalized de-intensification strategies. In addition, optimization studies indicate that advances in perioperative management and robotic technology may further improve functional outcomes, although high-quality evidence remains limited. Five key areas of research were identified, namely the optimization strategies, TORS as an alternative strategy, TORS for de-escalation, biomarker-driven de-escalation, and induction therapy.ConclusionTransoral robotic surgery demonstrates favorable oncological and functional outcomes, supporting its role as a de-intensification strategy in carefully selected patients with OPSCC. The integration of robust risk stratification methods, including biomarkers such as circulating cell-free HPV DNA (cfHPVDNA), holds promise for optimizing patient selection and tailoring treatment intensity. Continued advancements in robotic technology, along with the development of refined perioperative pain management strategies, may further enhance surgical precision and postoperative recovery.
